Medtronic Begins Trial for Next-Generation Drug-Eluting Stent in Small Arteries

Today Medtronic plc (NYSE: MDT) announced that it is beginning the U.S. pivotal trial for its new drug-eluting stent, the Resolute Onyx™. The Onyx received the European CE Mark in November and has been available in countries that recognize the CE Mark. The first phase of this trial will be studying one of the most challenging clinical scenarios: blockages in arteries that measure as small as 2.0mm. Normally drug-eluting stents are not used in arteries this narrow because of the increased incidence of stent thrombosis and restenosis. But the Onyx has thinner struts than the first and second generation DES devices and has shown positive outcomes in these narrow vessels.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news